• Login
    View Item 
    •   Home
    • UA Graduate and Undergraduate Research
    • UA Theses and Dissertations
    • Dissertations
    • View Item
    •   Home
    • UA Graduate and Undergraduate Research
    • UA Theses and Dissertations
    • Dissertations
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of UA Campus RepositoryCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsPublisherJournalThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsPublisherJournal

    My Account

    LoginRegister

    About

    AboutUA Faculty PublicationsUA DissertationsUA Master's ThesesUA Honors ThesesUA PressUA YearbooksUA CatalogsUA Libraries

    Statistics

    Most Popular ItemsStatistics by CountryMost Popular Authors

    Nonalcoholic Steatohepatitis Alters Phase I Drug Metabolism

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    azu_etd_16133_sip1_m.pdf
    Size:
    15.23Mb
    Format:
    PDF
    Download
    Author
    Li, Hui
    Issue Date
    2018
    Keywords
    Adverse Drug Reactions
    Alcohol Metabolism
    Cytochrome p450
    Nonalcoholic Steatohepatitis
    Phase I Metabolism
    Advisor
    Cherrington, Nathan J.
    
    Metadata
    Show full item record
    Publisher
    The University of Arizona.
    Rights
    Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author.
    Embargo
    Release after 05-Sep-2018
    Abstract
    Variable drug responses (VDRs) are dependent on inter-individual variability in the activity of drug-metabolizing enzymes. As the most common chronic liver disease in children and adults, nonalcoholic steatohepatitis (NASH) has been identified as a source of significant inter-individual variation in hepatic drug metabolism. A previous ex vivo study demonstrated significant changes in hepatic CYP activity in adult human NASH. To evaluate the current model in reflecting the hepatic CYP alterations in humans with NASH, the expression profile and the in vivo activities of multiple CYP isoforms were assessed in the prominent diabetic NASH mouse models. Although significant alterations in the profile of CYP expression and function were shown in the diabetic NASH mouse model, a comparison revealed that this model only partially recapitulates the human ex vivo CYP alteration pattern. Therefore, in vivo determination of the effects of NASH on CYP activity should be conducted in human, and more appropriate models are required for future drug metabolism studies in NASH. Compared to adults, children present age-related differences in pharmacokinetics and pharmacodynamics. The following study determined the impact of fatty liver disease severity on the activity of a variety of CYPs in adolescents using the in vivo approach established in the first study. The CYP2C19 enzymatic activity is decreased by 60% in NASH adolescents. A comparison between the in vivo pediatric studies and a previous ex vivo study in adult indicates distinct differences in the activities of CYP1A2 and CYP2C9, which demonstrate that pediatric NASH presents an altered pattern of CYP activity and NASH should be considered as a confounder of drug metabolism for certain CYPs. Furthermore, hepatic alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) play critical roles in alcohol metabolism and other cellular metabolism processes, as well as the metabolism of clinical drugs. The alterations in alcohol metabolism processes in response to human NASH progression were investigated using human liver samples. ADH and ALDH expression and function are significantly altered in the progression of NASH, which may have a notable impact on ADH and ALDH associated cellular metabolism processes and lead to significant alterations in drug metabolism mediated by these enzymes. Overall, the major phase I drug metabolizing enzymes are profoundly altered in the progression of human NASH, which may significantly increase the incidence of VDRs. Therefore, the disease state of NASH should be taken into consideration in dosage recommendations and appropriate dose adjustment. Future studies will be needed to translate these findings to guide actual clinical practice.
    Type
    text
    Electronic Dissertation
    Degree Name
    Ph.D.
    Degree Level
    doctoral
    Degree Program
    Graduate College
    Pharmacology & Toxicology
    Degree Grantor
    University of Arizona
    Collections
    Dissertations

    entitlement

     
    The University of Arizona Libraries | 1510 E. University Blvd. | Tucson, AZ 85721-0055
    Tel 520-621-6442 | repository@u.library.arizona.edu
    DSpace software copyright © 2002-2017  DuraSpace
    Quick Guide | Contact Us | Send Feedback
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.